Why Some Arrhythmias Are Ablated
Ablation works when the mechanism lives in a place you can reach and destroy. The logic is entirely about geography.
Every arrhythmia that can be cured by ablation shares one feature: the mechanism depends on a specific, discrete piece of tissue.
Destroy that tissue, and the arrhythmia has no substrate left. It cannot exist. This sounds simple, but the entire intellectual challenge of the EP lab is figuring out which piece of tissue matters and why the rhythm can't survive without it.
The answer always comes back to mechanism. Every chapter of this story — from ion channels to reentry to entrainment — has been building toward this question: once you understand how the rhythm works, can you find a physical location to interrupt it permanently?
Focal Sources: One Spot, One Burn
The simplest ablation targets are focal arrhythmias — rhythms that originate from a single abnormal cell cluster firing inappropriately. Atrial tachycardia from a pulmonary vein focus. Outflow tract PVCs from a small nest of triggered cells in the RVOT. Focal junctional tachycardia from near the His bundle.
In these cases, the mechanism is abnormal automaticity or triggered activity arising from a point source. Activation mapping (Volume VI) reveals a centrifugal spread from one earliest site. You place the catheter there, deliver radiofrequency energy, and the arrhythmia stops. It stops because the cells responsible are destroyed. There is no circuit to reroute, no alternative pathway to take over. The source is gone.
This is why outflow tract VT and many focal atrial tachycardias have ablation success rates above 90%. The target is small, the mapping is unambiguous, and the surrounding tissue is healthy. One lesion, one cure.
Fixed Circuits: Cut the Loop
Reentrant arrhythmias are ablatable when the circuit is constrained to travel through a narrow, obligate corridor. If every lap of the wavefront must pass through a specific isthmus, destroying that isthmus breaks the loop permanently.
The circuit uses the slow pathway as one limb. The slow pathway sits in a defined anatomical zone near the coronary sinus os. Ablating that region eliminates the slow pathway, and the circuit can never form again. The fast pathway (the normal AV conduction route) is preserved. Success rate: >95%.
The circuit requires an accessory pathway that bypasses the AV node. This pathway crosses the AV groove at a single point. Ablating that point disconnects the pathway completely. The wavefront can no longer get from ventricle back to atrium (or vice versa) via the bypass tract. Without both limbs, the loop dies.
The macro-reentrant loop circles the right atrium. Every lap must pass through the cavotricuspid isthmus (CTI) — the narrow strip of tissue between the tricuspid annulus and the inferior vena cava. A line of ablation lesions across this isthmus creates a permanent barrier. The wavefront arrives at the line, finds no viable tissue, and cannot continue. The circuit is physically interrupted.
The reentrant circuit weaves through surviving muscle bundles within scar tissue. The critical isthmus — the narrow channel of viable myocardium between dense scar regions — is where the wavefront is most vulnerable. Ablating across this isthmus blocks the only path through the scar. The circuit has no detour. This is more challenging because scar can harbor multiple circuits, but the logic is the same: find the bottleneck, close it.
When the Target Isn't Discrete
Ablation struggles when the mechanism is diffuse — when there is no single spot or narrow corridor to target. Atrial fibrillation is the classic example. The chaotic wavelets that sustain AFib don't travel through a single isthmus. They wander across the entire atrial surface, breaking and reforming constantly.
Pulmonary vein isolation (PVI) works for many patients because the pulmonary veins are a common trigger zone. Electrically disconnecting them removes the sparks that initiate fibrillation. But in patients with longstanding, persistent AFib, the atrial tissue itself has remodeled: fibrosis is widespread, the wavelets are self-sustaining, and isolating the veins doesn't stop the chaos because the substrate has spread beyond any discrete target.
The same principle applies to polymorphic VT in diffuse cardiomyopathy, where the reentrant substrate is a broad region of patchy fibrosis with no single critical isthmus. You can ablate one circuit, but the tissue supports others. This is why ablation in these settings reduces burden but rarely cures.
The Ablation Decision Tree
The decision to ablate follows from three questions, each rooted in mechanism:
A focal source, an accessory pathway, or a critical isthmus. If the mechanism requires a specific piece of tissue, ablation is an option.
Some targets sit near the His bundle (risking complete heart block), on the epicardium (requiring pericardial access), or deep within thick myocardium (limiting lesion depth). Anatomy determines feasibility.
A young patient with weekly symptomatic AVNRT has a clear benefit from ablation. A patient with rare, asymptomatic PVCs may not. The mechanism tells you what's possible; clinical context tells you what's wise.
The single most important predictor of ablation success is whether the operator can identify and reach the critical substrate. In typical atrial flutter, the CTI is predictable and accessible — success rates exceed 95%. In epicardial VT from non-ischemic cardiomyopathy, the substrate may be on the outside of the heart, buried under fat, near the phrenic nerve. The mechanism is still reentry, but the geography makes it harder.
This is why experienced electrophysiologists think in terms of substrate, not diagnosis. "VT" is not a single disease — it's a family of mechanisms in different anatomical contexts. The same reentrant logic that makes CTI flutter trivially ablatable can make epicardial VT extraordinarily difficult. The mechanism is identical. The anatomy changes everything.
Key Takeaways
- Ablation cures focal arrhythmias by destroying the single abnormal source. If the activation map shows centrifugal spread from one point, one lesion eliminates the rhythm.
- Ablation cures reentrant arrhythmias when the circuit has a narrow, obligate isthmus. Blocking that corridor permanently breaks the loop — the principle behind CTI ablation, slow pathway modification, and scar VT isthmus ablation.
- Ablation struggles with diffuse substrates. Atrial fibrillation in remodeled atria, polymorphic VT in diffuse cardiomyopathy, and multifocal tachycardias lack a single target. Ablation can reduce burden but may not cure.
- The mechanism predicts the target; the anatomy determines whether you can reach it safely. Geography — proximity to the His bundle, phrenic nerve, coronary arteries — shapes procedural risk.
- The decision to ablate requires a discrete target, safe access, and a risk-benefit ratio that favors the procedure. All three must be present.